Upload
hoangnga
View
215
Download
0
Embed Size (px)
Citation preview
207
16, Chuoku. Sapporo 060. Cancer Chemolher Pharmacol 1990;26:373-
6.
A tol;tl of 47 patients with unresectable non-small-cell lung cancer
weretrcmed witharcglmen conslstmgofwplatin (CDDP. lOOmg/m),
lfosfamide(IFX,2g/m*x 3; with mcsna)andvindesine(VDS,3 mg/m’)
(CIV). Tlus regimen was given over a 3. or 5.week period. Among 40
completely cvaluable patienB, 19 partial responses (PRs) were ob-
wved,forarcsponseratcof47.5% (78.6% insquamous-cellcarcinoma
and 30. I B in adeno-and large-cell carcmoma); no complete responses
(CRs) were ohtamed. The hcmatologic toxicity was not severe, but the
renal toxicitywasrather high;twopatwnlsdevelopedacuterenal failure
and died of subsequentpancytopcnla and sepsis. We concluded that the
CIV rcglmen was more effective, especially agamst squamous-cell
carcinoma, but more toxic than the combination of CDDP and VDS for
non-small-cell lung cancer and rhat candidates for ihis therapy must be
carefully chosen.
Quality of life assessment during chemotherapy for non-small cell
lung cancer
Maasiha PK, Raulonen JK, Mattson MT, Mattson KV. Deparrmen! of
PulmonaryMedicine.Ijelslnki L~niversiryCen~ralllospilal,Ilaartman-
uduztu 4. 00290 Ilelsinki. Eur .I Cancer 1990:26:706-8.
Quality of hfc was assessed by linear analogue scales for patients
wth non-small cell lung cancer parliclpating m a phase I-II trial.
Chcmothcrapy consisted of cyclophosphamide 600 mg/m’ intrave-
nously on day 1 and uimctrexatc (five dose levels) intravenously on
days 1 -S, repealed every 21 days. Elcvcn subjective items wereassessed
hy the patmnts. Nme of the scales related to performance, problems
related to the disease itselfand uncertainty about the value of ueatmcnt:
two scales relalcd LO the major known side-effccls of chemotherapy.
Each paticm completed the scales before treatmcnt, on the last day of
treatment (day 5) and once bctwccn cycles. Variatron in the scores for
Items (e.g. for nausea or appetite) suggests that the method was useful
m estimating the patlem’s perceived quality of life during repeated
cycles of chemotherapy. Compliance was good and the method was
easily accepted by both patients and nurses as part of a routine.
Aerosol application of interferon-alpha in the treatment of bronchi-
oloalveolar carcinoma
Van ZandwiJk N, Jassem E, Dubbclmann R, Braat MCP, Rumke P.
Departmew of Medical Oncology, The Nelherlands Cancer Inslrlule,
Piesmanlaan 121.1066 CXAmsu~dum. Eur JCanccr 1990:26:738-40.
IO patients with locally advanccd bronchioloalvcolar carcinoma
were treated with interferon-alpha as an inhaled aerosol. Imtial doses
ranged between 1 and 10 MU dally or thrice weekly and were then
increased to 20 MU dally. Trcalmcnc was contmued until dwase
progression or exccssivc loxlctly occurred. 9 pauents wcrc evaluable
for toxlcrty. In 1 case ucatmcnt had to bc slopped after 2 weeks due (0
fever, fatigue and progressive dyspnoea. 2 patients developed fever, 1
had malaw, fatigue and loss of appctltc and 2 had dose-dependent
transient dyspnoea. According to standard criteria no turnour responses
could be detected. In 6 out of 8 evaluated for response Lo interferon,
radiological stabilisauon of dlscase for 7-43 weeks (me&an 15) was
observed. These resulu poml LO the fcasibihty of aerosol inhalauon of
mtcrferon-alpha, but also to its hmlted antitumour actiwty m locally
advanced bronchioloalveolar carcmoma.
Effect of inhaled natural interferon-alphaondiffuse bronchioalveo-
lar carcinoma
Kmnula V, Camel1 K, Mat&on K. Deparrmem ofFulmonory Medicine. Helsmki Univerwy Cenrral Ijospilal, llaorlmaninkalu 4,00290 IMsinki.
Ear J Cancer 1990;26:740-1.
Six patients wilh diffuse bronchloalveolarcarcinoma confined Lo the
thorax were treated with mwrferon-alpha by inhalation. The dose was
1 or 6 MU thrice daily. Therapy was continued unld the tumour
progressed or bronchial hyperreactwlty became unacceptable. The
treatment was not effective.
A pilot study with aa ifosfamide, carboplatin and etoposide regimen
(ICE) in patients with advanced non-small-cell lung cancer
Scalier JP, Bron D, Sergysels R, Klaslersky J. Clinique des V&s
Rrsprratorres. lloprral Sami-P~rre. Universite Libre de Bruxelles.
Drug Invest lYYO;2:31-7.
A phase I study wth Ihe combmation of lfosfamidc + carboplatm +
ctoposide (ICE) was conducted in patients with advanced non-small-
cell lung cancer (NSCLC). Patients who had had prcwous therapy wcrc
given tic following dosages: ifosfarmdc 2 g/m’ on days 1 to 3,
carboplatin 75 mg/m”on days 1 and 2, and ctoposidc X0 mg/m’on days
1 and 2. In those with no prcviow Ihcrapy, carboplatm 75 mg/m’ was
admimstered on days 1 IO 3. In 15 treated patients, 3 objectlvc responses
were documcmcd, all from the 7 patients wllh no prior therapy. The
dose hmiting toxicity was Icucopema. A phase II study IS required to
dctermmc the exact activity 01. the combmatlon m patients wth ad-
vanced NSCLC. Two paficnts wth hmitcd NSCLC wcrc ueatcd wth
high doses ICE (ifosfamlde 6 g/m2 on day I ; carboplatm 400 mg/m* on
days 1 and 2, and etoposidc 500 mg/mt on days I and 2) and autologous
bone marrow mfusion followed by local Lhcrapy. Toxuty was acccpt-
able. Responses wcrc of short duration (IO months) and both patrcnts
died 11 and 15 months, rcspcctlvcly, after the start of Ihcrapy.
The use of clonogenic assays in assessing the response of human lung
cancer cell lines to a and gamma interferons alone or in combina-
tion with adriamycin
Jabbar SAB, Twentyman PR. Medual Rrsearch Councd. C/mica1
Oncology and Radiorherapeuucs Unir, /fills Road. Camhrldge CB2
2Qll. Int I Cancer 1990;46:546-51.
The antiproliferative and cytotoxic effects of purlfxxi IFN-a and
recombmam IFN-gamma were mvcstigatcd usmg both duect cell
counting and aclonogcnic assay on a panel of 5 eslabhshcd human lung
cancer cell lmes and for 2 of them also on thcu muludrug-rwslant
counterparts. There was considerable hclerogcmxy m the response of
thecclllincstothcIFNsm termsofgrowthinhibitlon. Clonogcmcassay
of IFN-treated cells indlcatcd that, where a cell lme had responded
markedly 10 an IFN, only a small fractmn of the cells remammg after
IFN lreatmcnt were clonogemcally wablc. When cell\ wcrc placed mto
the clonogcmc assay m the prcscncc of IFNs, the t~mc course of colony
formation was diffcrcnt from that seen in the control culturca for mosL
of the cell lines. The measured ‘surviving fracuon’ was greatly depend-
ent upon the time of colony counting. When the effcct~ of IFNs in
combination with ADM were studied, conclusions regarding the mtcr-
action of the effects of Ihe agents also depended upon the tlmc at which
colomcs were counted.
A randomized study comparing cisplatin or carhoplatin with eto-
poside in patients with advanced non-small-cell lung cancer: Euro-
pean OrgaoizHion for Research and Treatment of Cancer Protocol
07861
Klastcrsky I, Sculicr JP, Lacrolx H CL al. lnslirur ./ule.\ Border. Rut,
/je#er-Border I. 1000 Brurlies J Clm Oncol lY9O;X: 1556.62.
The European Organuatmn for Rcscarch and Trcatmcnt of Cancer
(EORTC) Lung Cancer Working Party conducted a randomI& trial
comparmg c~splatin (CDDP: I20 mg/m*, day 1) and carboplatm (CBDCA:
325 mg/m*, day I) m combmatlon wth cloposldc (VPlh: 100 mg/m2,
days I, 2,and3) madvanccdnon-small-cell lungcanccr(NSCLC).Two
hundred twenty-eight patients wcrc chglble for saw& and 202assess.
able for rcsponsc. WC obtamed 27 of 100 objcctivc rcsponscs (ORs;
27%) m the CDDP arm and 16 of 102 (16%) in the CBDCA arm (p =
.07). Thcrc was no slgnifxant difference m survival. Toxuty, consIs1-
mg mainly of myclosupprewon and renal functmn Impairmcm, was
sigmficamly increased m the patients rcccwng the CDDP ucauncnt.
Wcconcludc IhatCDDPplus VPl6wasmorcaclwe bulalsomorc toxic
than CBDCA plus VP16 in advanced NSCLC.
Non-P-glycoprotein mediated mechanism for multidrug resistance
precedes P-glycoprotein expression during in vitro selection for
doxorobicin resistance in a human lung cancer cell line
Baas F, Jongsma APM, Broxterman HJ ct al. Divisron of Molecular Bwlogy, TheNeiherlands Cancerlnsliiute. Pla.wumlann 121,1066 CX
Amverdam. Cancer Rcs 1990;50:5392-8.
Two dlffercnt mechanisms lhat contrlbutc to muludrug resistance
(MDR) were found m dcrwatives of the human squamous lung cancer cell line SW-1573. The parental ccl1 lmc has a low amoum of mdrl P-